Biovie Inc. ((BIVI)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioVie Inc. is conducting a clinical study titled A Double-Blind, Randomized, Placebo-controlled, Study of NE3107 in Subjects With Early Parkinson’s Disease. The study aims to evaluate the effectiveness of bezisterim in reducing movement symptoms in Parkinson’s patients aged 45 to 80, who have not yet started treatment with levodopa. This research is significant as it explores a potential new treatment avenue for early-stage Parkinson’s patients.
The intervention being tested is NE3107, an experimental drug administered orally at 20 mg twice daily. The study compares this treatment to a placebo to assess its efficacy in alleviating Parkinson’s symptoms.
The study follows an interventional, randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment assignments. The primary purpose of the study is treatment-focused.
The study began on December 24, 2024, with a primary completion date yet to be announced. The latest update was submitted on July 16, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update from BioVie Inc. could influence investor sentiment positively, as successful outcomes may enhance the company’s market position and stock performance. The study’s progress is also relevant in the context of the competitive landscape of Parkinson’s disease treatments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.